Litcius/Paper detail

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA

Cheng Wang, Heng Luo, Xinye Chen, Yonglei Zhang, Dehua Lu, Xingchen Liu, Fucheng Yin, Shang Li, Lingyi Kong, Xiaobing Wang, Xiaobing Wang

2023Bioorganic Chemistry20 citationsDOI

Topics & Concepts

OlaparibTriple-negative breast cancerPoly ADP ribose polymerasePalbociclibChemistryCyclin-dependent kinase 6Cancer researchPARP inhibitorPARP1Synthetic lethalityWild typeCancerIC50Breast cancerPolymeraseBiologyMedicineInternal medicineIn vitroDNA repairCell cycleCyclin-dependent kinaseBiochemistryMetastatic breast cancerDNAMutantGenePARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesCancer therapeutics and mechanisms
Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA | Litcius